Fenofibrate

Material: Phenophybate 200mg Capsules and 160 mg Tablet

Instructions: Friedrichson type IIa, IIb, III, IV and V hyperlipidemia are applied in addition to diet control in patient care. 

Dimensions and Usage Rules: 1 200mg Capsule or 1 160 mg Tablet a day. 

Alerts and in which cases can not be used: severe losers and liver function, circulatory primary circulation and patients whose liver function is always abnormal due to unknown, early patients' disease and those who are extremely sensitive to phenophibre. 

Side effects: Hepatitis, gallstones, piles of gallstones, liver progression, muscular pain, muscular weakness, rhabdomyomycosis, light sensitivity, eczema, peripheral edema, enzina, chest rash, spinal movement and migraine.

 Response to other drugs: oral antioxidants and psychosporin.

 Use during pregnancy and breastfeeding: If pregnancy is more than a child's risk, then it can be used carefully during pregnancy. Nursing mothers can not be used.

āωāĻĒাāĻĻাāύ : āĻĢেāύোāĻĢাāχāĻŦ্āϰেāϟ ⧍ā§Ļā§Ļ āĻŽি.āĻ—্āϰা. āĻ•্āϝাāĻĒāϏুāϞ āĻ“ ā§§ā§Ŧā§Ļ āĻŽি.āĻ—্āϰা. āϟ্āϝাāĻŦāϞেāϟ ।

āύিāϰ্āĻĻেāĻļāύা : āĻĢ্āϰেāĻĄāϰিāĻ•āϏāύ āϟাāχāĻĒ IIa, IIb, III, IVāĻāĻŦং V āĻšাāχāĻĒাāϰāϞিāĻĒিāĻĄিāĻŽিāϝ়া āϰোāĻ—ীāϰ āϚিāĻ•িā§ŽāϏাāϝ় āĻ–াāĻĻ্āϝ āύিāϝ়āύ্āϤ্āϰāĻŖেāϰ āĻĒাāĻļাāĻĒাāĻļি āĻĒ্āϰāϝ়োāĻ— āĻ•āϰা āĻšāϝ়।

āĻŽাāϤ্āϰা āĻ“ āĻŦ্āϝāĻŦāĻšাāϰ āĻŦিāϧি : ā§§āϟি ⧍ā§Ļā§Ļ āĻŽি.āĻ—্āϰা. āĻ•্āϝাāĻĒāϏুāϞ āĻŦা ā§§ āϟি ā§§ā§Ŧā§Ļ āĻŽি.āĻ—্āϰা. āϟ্āϝাāĻŦāϞেāϟ āĻĻিāύে āĻāĻ•āĻŦাāϰ।

āϏāϤāϰ্āĻ•āϤা āĻ“ āϝেāϏāĻŦ āĻ•্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻ•āϰা āϝাāĻŦে āύা : āϝāĻ•ৃāϤেāϰ āĻāĻŦং āĻŦৃāĻ•্āĻ•েāϰ āϤীāĻŦ্āϰ āĻ…āĻ•াāϰ্āϝāĻ•াāϰিāϤা, āĻĒ্āϰাāĻĨāĻŽিāĻ• āĻŦিāϞিāϝ়াāϰী āϏিāϰোāϏিāϏ āĻāĻŦং āϝেāϏāĻŦ āϰোāĻ—ীāϰ āϞিāĻ­াāϰ āĻĢাংāĻļāύ āϏāϰ্āĻŦāĻĻা āĻ…āϜাāύা āĻ•াāϰāĻŖে āĻ…āϏ্āĻŦাāĻ­াāĻŦিāĻ•, āφāĻ—ে āĻĨেāĻ•ে āĻ›িāϞ āĻāĻŽāύ āĻĒিāϤ্āϤāĻĨāϞিāϰ āĻ…āϏুāĻ– āĻāĻŦং āϝাāϰা āĻĢেāύোāĻĢাāχāĻŦ্āϰেāϟেāϰ āĻĒ্āϰāϤি āĻ…āϤিāϏংāĻŦেāĻĻāύāĻļীāϞ।

āĻĒাāϰ্āĻļ্āĻŦ āĻĒ্āϰāϤিāĻ•্āϰিāϝ়া : āĻšেāĻĒাāϟাāχāϟিāϏ, āĻĒিāϤ্āϤāĻĨāϞিāϰ āĻĒাāĻĨāϰ, āĻĒিāϤ্āϤāĻĨāϞিāϰ āĻĒ্āϰāĻĻাāĻš, āϝāĻ•ৃāϤেāϰ āĻŦৃāĻĻ্āϧি, āĻŽাংāϏāĻĒেāĻļীāϰ āĻŦ্āϝāĻĨা, āĻŽাংāϏāĻĒেāĻļীāϰ āĻĻুāϰ্āĻŦāϞāϤা, āϰ্āϝাāĻŦāĻĄোāĻŽাāϝ়োāϞাāχāϏিāϏ, āφāϞোāĻ• āϏংāĻŦেāĻĻāύāĻļীāϞāϤা, āĻāĻ•āϜিāĻŽা, āĻĒেāϰিāĻĢেāϰাāϞ āχāĻĄিāĻŽা, āĻāύāϜিāύা, āĻŦুāĻ• āϧāĻĄ়āĻĢāĻĄ়, āύাāĻĄ়ীāϰ āĻ—āϤি āĻŦৃāĻĻ্āϧি āĻāĻŦং āĻŽাāχāĻ—্āϰেāύ।

āĻ…āύ্āϝাāύ্āϝ āĻ“āώুāϧেāϰ āϏাāĻĨে āĻĒ্āϰāϤিāĻ•্āϰিāϝ়া : āĻ“āϰাāϞ āĻāύ্āϟিāĻ•োāϝ়াāĻ—ুāϞেāύ্āϟ āĻāĻŦং āϏাāχāĻ•োāϏ্āĻĒোāϰিāύ।

āĻ—āϰ্āĻ­াāĻŦāϏ্āĻĨা āĻ“ āϏ্āϤāύ্āϝāĻĻাāύāĻ•াāϞে āĻŦ্āϝāĻŦāĻšাāϰ : āϝāĻĻি āĻ—āϰ্āĻ­āϏ্āĻĨ āϏāύ্āϤাāύেāϰ āĻুঁāĻ•িāϰ āϚেāϝ়ে āωāĻĒāĻ•াāϰ āĻŦেāĻļী āĻšāϝ় āϤāĻŦে āϏāϤāϰ্āĻ•āϤাāϰ āϏাāĻĨে āĻ—āϰ্āĻ­াāĻŦāϏ্āĻĨাāϝ় āĻŦ্āϝāĻŦāĻšাāϰ āĻ•āϰা āϝেāϤে āĻĒাāϰে। āύাāϰ্āϏিং āĻŽাāϝ়েāϰ āĻ•্āώেāϤ্āϰে āĻŦ্āϝāĻŦāĻšাāϰ āĻ•āϰা āϝাāĻŦে āύা।

Post a Comment

Previous Next

Ų†Ų…ŲˆØ°ØŦ Ø§Ų„Ø§ØĒØĩØ§Ų„